Start exploring the options of dialysis, transplantation, or conservative management with patients at least a year before they are likely to need it
Recommend patients start dialysis at an estimated glomerular filtration rate (eGFR) of 5-7 mL/min/1.73 m² or sooner if symptoms of their chronic kidney disease are affecting their daily life
Haemodiafiltration is a form of haemodialysis with additional convection and is more effective than standard haemodialysis with a similar patient experience
Transplantation has better outcomes than any form of dialysis, with pre-emptive transplantation being more effective than transplantation after dialysis
Patients should not be excluded from receiving a kidney transplant based on body mass index alone
Approximately 8000 people a year start renal replacement therapy in the UK.1 Box 1 describes the options available for people approaching the need for renal replacement therapy. Around 60 000 people are currently living with a kidney transplant or are receiving dialysis. Transplant is the most common form of renal replacement therapy (approximately 54% of prevalent renal replacement therapy patients), followed by haemodialysis (40%), and then peritoneal dialysis (6%).1 The number of new transplants was around 3000 in 2016; this has gradually increased more recently. Some people will receive a kidney from a living donor, but those who have to join the waiting list for a kidney donation can expect to wait for 2.5-3 years.2 Among those receiving dialysis, most people opt for haemodialysis or haemodiafiltration done at hospital or in a satellite centre rather than at home.
Renal replacement therapy comprises either transplantation or dialysis. Some people decide not to receive renal replacement therapy but choose conservative management, which comprises full supportive management (including advance care planning and control of symptoms and complications).
Can be from living or deceased donors
Can be done pre-emptively (before the point at which dialysis …

中文翻译：

---

肾脏替代疗法：NICE指南摘要

至少在可能需要它的一年之前，
开始与患者探讨透析，移植或保守治疗的方法。建议患者以估计的肾小球滤过率（eGFR）为5-7 mL / min / 1.73 m ²或以下开始透析越早如果他们的慢性肾脏病的症状影响日常生活
血液透析滤过是额外的对流血液透析的一种形式，是不是有类似患者体验标准的血液透析更有效的
移植具有比任何形式的透析的更好的结果，以先发制人的移植幸福比透析后的移植更有效
不应仅根据体重指数将患者排除在接受肾脏移植之外
在英国，每年大约有8000人开始进行肾脏替代治疗。1方框1说明了需要进行肾脏替代治疗的人们可以使用的选项。目前约有6万人正在接受肾脏移植或正在接受透析。移植是最常见的肾脏替代治疗形式（约占普通肾脏替代治疗患者的54％），其次是血液透析（40％），然后是腹膜透析（6％）。1 2016年的新移植数量约为3000个；最近，这种情况逐渐增加。有些人会从活着的捐献者那里得到肾脏，但是那些必须加入肾脏捐赠等待名单的人可能会等待2.5-3年。2个在接受透析的患者中，大多数人选择在医院或在卫星中心而不是在家中进行血液透析或血液透析滤过。
肾脏替代疗法包括移植或透析。有些人决定不接受肾脏替代治疗，而是选择保守治疗，包括全面的支持治疗（包括预先护理计划以及症状和并发症的控制）。
可以来自活着的或已故的捐助者，
可以先发制人（在透析之前……）